The recent approval of Novartis AG's Diovan/HCT and Exforge as a first-line, single pill combination for high blood pressure represents an approach to treatment that has become standard practice for many physicians - a sign that doctors are likely to embrace this latest product. (BioWorld Financial Watch)

Cytochroma hopes to advance its three lead products for kidney disease patients, with an infusion of cash from the closing of a C$45 million (US$44 million) Series C financing and C$105 million licensing deal with Japanese drugmaker Mitsubishi Tanabe Pharma Corp. (BioWorld Today)